Finance

Lists
LUNA:VIE
H Lundbeck A/S Class A
€6,64
+0,76%
(+0,050) 1D
30 Okt., 15:30:23 GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for LUNA...
Open
€6,64
High
€6,65
Low
€6,64
Mkt. cap
53,20 mjd
Avg. vol.
85,00
Volume
0,00
52-wk high
€6,67
52-wk low
€4,22
No. of employees
5 k
Open
€6,64
High
€6,65
Low
€6,64
Mkt. cap
53,20 mjd
Avg. vol.
85,00
Volume
0,00
52-wk high
€6,67
52-wk low
€4,22
No. of employees
5 k
News stories
From web sources and news partners
Profile
H. Lundbeck A/S, commonly referred to as Lundbeck, is a Danish international pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at brain diseases, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease and migraine. Wikipedia
About H Lundbeck A/S Class A
CEOCharl Van Zyl
Employees5 k
Founded1915
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in DKK
Loading Previous Earnings...
Revenue
Net income
All values in DKK
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
6,28 mjd
6,09 mjd
7,12 mjd
6,46 mjd
Cost of goods sold
846,00 m
1,24 mjd
1,30 mjd
1,27 mjd
Cost of revenue
846,00 m
1,24 mjd
1,30 mjd
1,27 mjd
Research and development expenses
1,16 mjd
820,00 m
1,38 mjd
1,43 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,15 mjd
2,54 mjd
2,13 mjd
2,28 mjd
Operating expense
3,31 mjd
4,36 mjd
3,52 mjd
3,70 mjd
Total operating expenses
4,16 mjd
5,60 mjd
4,82 mjd
4,96 mjd
Operating income
2,12 mjd
490,00 m
2,31 mjd
1,50 mjd
Other non operating income
-
-32,00 m
-
-
EBT including unusual items
1,41 mjd
360,00 m
2,13 mjd
1,47 mjd
EBT excluding unusual items
1,90 mjd
567,00 m
2,28 mjd
1,47 mjd
Income tax expense
311,00 m
387,00 m
468,00 m
323,00 m
Effective tax rate
22,03%
107,50%
22,01%
21,96%
Other operating expenses
-
997,00 m
-
-11,00 m
Net income
1,10 mjd
-27,00 m
1,66 mjd
1,15 mjd
Net profit margin
17,53%
-0,44%
23,27%
17,76%
Earnings per share
1,44
0,94
2,16
1,54
Interest and investment income
-
199,00 m
-
-
Interest expense
-219,00 m
-83,00 m
-29,00 m
-27,00 m
Net interest expenses
-219,00 m
116,00 m
-29,00 m
-27,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
2,55 mjd
956,00 m
2,78 mjd
1,98 mjd
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google-programme